Literature DB >> 2042398

Simultaneous expression of the Lassa virus N and GPC genes from a single recombinant vaccinia virus.

H G Morrison1, C S Goldsmith, H L Regnery, D D Auperin.   

Abstract

A new transfer vector was constructed that directs the insertion of two heterologous genes into the vaccinia virus thymidine kinase (TK) gene during a single recombination event. This vector, pDAVAC2, contains bidirectional vaccinia P7.5 early/late promoter elements and two unique cloning sites. cDNA clones containing the complete coding sequences for the Lassa virus (Josiah strain) nucleoprotein (N) and glycoprotein (GPC) genes were inserted into the vaccinia TK gene using this transfer vector. The recombinant virus, V-LSGN-II, expressed proteins in cell culture that appeared to be authentic with respect to electrophoretic mobility, glycosylation, and post-translational cleavage. Indirect immunofluorescence (IFA) of recombinant virus-infected cells demonstrated both the bright granular and diffuse patterns of staining characteristic of the Lassa nucleoprotein and glycoprotein, respectively. Electron-dense inclusion bodies typical of arenavirus-infected cells were observed by electron microscopy in V-LSN and V-LSGN-II-infected cells, but not in V-LSGPC-infected cells. Mice inoculated with V-LSGN-II by intraperitoneal injection developed serum antibodies that reacted with authentic Lassa proteins in immunofluorescence and radioimmune precipitation assays. This recombinant virus represents an additional candidate for a Lassa fever vaccine and demonstrates the feasibility of expressing any two genes of interest in a single recombinant vaccinia virus through the use of the transfer vector pDAVAC2.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2042398     DOI: 10.1016/0168-1702(91)90021-m

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  6 in total

1.  Common antiviral cytotoxic t-lymphocyte epitope for diverse arenaviruses.

Authors:  M B Oldstone; H Lewicki; D Homann; C Nguyen; S Julien; J E Gairin
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Immunogenicity and relative attenuation of different vaccinia-rabies virus recombinants.

Authors:  J H Zhu; J Wang; B Cai; W Zhao; Y Zhu; R Chao; L Chen; H Xue; B L Ying; C P Li; Q L Hu; J Sha; J J Esposito
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

3.  Effective vaccine for lassa fever.

Authors:  S P Fisher-Hoch; L Hutwagner; B Brown; J B McCormick
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

Review 4.  VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.

Authors:  Pierre Leblanc; Leonard Moise; Cybelle Luza; Kanawat Chantaralawan; Lynchy Lezeau; Jianping Yuan; Mary Field; Daniel Richer; Christine Boyle; William D Martin; Jordan B Fishman; Eric A Berg; David Baker; Brandon Zeigler; Dale E Mais; William Taylor; Russell Coleman; H Shaw Warren; Jeffrey A Gelfand; Anne S De Groot; Timothy Brauns; Mark C Poznansky
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Cross-protection of mice against a global spectrum of rabies virus variants.

Authors:  D L Lodmell; J S Smith; J J Esposito; L C Ewalt
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

Review 6.  Serological assays based on recombinant viral proteins for the diagnosis of arenavirus hemorrhagic fevers.

Authors:  Shuetsu Fukushi; Hideki Tani; Tomoki Yoshikawa; Masayuki Saijo; Shigeru Morikawa
Journal:  Viruses       Date:  2012-10-12       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.